XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 59 filers reported holding XENON PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,305,116 | +24.7% | 126,028 | +40.5% | 0.01% | -15.4% |
| Q2 2023 | $3,453,604 | -8.4% | 89,704 | -14.8% | 0.01% | -76.8% |
| Q1 2023 | $3,769,832 | +10.5% | 105,332 | +21.7% | 0.06% | -9.7% |
| Q4 2022 | $3,411,365 | +7.4% | 86,517 | -1.7% | 0.06% | +1.6% |
| Q3 2022 | $3,176,000 | -35.5% | 87,971 | -45.7% | 0.06% | -55.1% |
| Q2 2022 | $4,926,000 | +4.4% | 161,927 | +4.9% | 0.14% | +7.9% |
| Q1 2022 | $4,717,000 | +109.7% | 154,308 | +114.4% | 0.13% | +80.0% |
| Q4 2021 | $2,249,000 | +2126.7% | 71,984 | +841.3% | 0.07% | +48.9% |
| Q3 2018 | $101,000 | – | 7,647 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |